FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Vaccine Passports Are ‘Reintroducing Politics into the Vaccine Conversation'

Vaccine Passports Are ‘Reintroducing Politics into the Vaccine Conversation'

A vaccine passport is not a get-out-of-pandemic card, but it could feel like one. Former FDA associate commissioner Peter...  Read more

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

...  Read more

J&J vaccine 'safe and effective': Former FDA associate commissioner

J&J vaccine 'safe and effective': Former FDA associate commissioner

CMPI president Peter Pitts weighs in on the pause of the Johnson & Johnson vaccine across the country....  Read more

DRUGWONKS BLOG